6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

EFFECT - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

EFFECT - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

S-8 - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

POS AM - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Maxim Group initiated coverage of NeuroSense Therapeutics with a rating of Buy and set a new price target of $7.00

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial evaluating PrimeC for Alzheimer's disease (AD). Using NeuroKaire's proprietary technology to generate brain cells from each patient's blood, analysis of samples from clinically characterized AD patients demonstrated that:  Pri

Financing at 40% premium to market price provides near-term bridge to anticipated milestones CAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a definitive agreement with a single investor for a $500,000 private placement of ordinary shares. Under the terms of the agreement, NeuroSense will issue 333,334 ordinary shares at a purchase price of $1.50 per share, representing a 40% premium to the closing price of the Company's ordinary shares on September 3, 2025. The private placement is expec

CAMBRIDGE, Mass., July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and financial results of the first half of 2025. NeuroSense is advancing PrimeC, its investigational combination therapy for amyotrophic lateral sclerosis (ALS), through regulatory pathways while preparing for a pivotal Phase 3 trial. "The first half of 2025 has been transformational for NeuroSense. We regained compliance with Nasdaq's stockholders' equity requirement, generated additional long–term data from our

Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones & Go-to-Market Options in a Must-Watch Event CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, updates today that in a live broadcast, NeuroSense CEO Alon Ben-Noon will join Aaron Lazar, Celebrated TV and film actor and Broadway star who has become a powerful new advocate in the fight against ALS following his recent diagnosis.

NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it has successfully scaled-up its production of PrimeC to commercial scale, marking a significant step toward bringing this potential disease-modifying ALS therapy to patients, following the promising efficacy data demonstrated in the Phase 2b PARADIGM study. NeuroSense has stra

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today issued a shareholder letter from Chief Executive Officer Alon Ben-Noon. The letter provides an update on the company's ongoing partnership discussions, regulatory and commercial pathway for PrimeC in ALS, clinical progress, and financial outlook

New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ:NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its Phase 2b PARADIGM clinical trial. The data highlights the significant impact of PrimeC, the company's investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS), on microRNA (miRNA) modulation. These data are particularly significant because they: Represent an important development in understanding how

Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional declineOngoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization Phase 3 study design for PrimeC in ALS aligned with FDA; planned initiation in 2025CAMBRIDGE, Mass., April 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reports its financial results for the year ended December 31, 2024 and provides a business update. Business highlights from 2024 and to date PrimeC achieved p

Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense CAMBRIDGE, Mass., April 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ:NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced that two members of its Scientific Advisory Board will present new data from the Company's Phase 2b trial during the General Neurology and Late Breaker sessions at the 77th Annual American Academy of Neurology (AAN) Meeting. The presentations and conference will be taking place in San Diego, CA on April 8, 2025. Jeremy Shefner, M

NeuroSense's Groundbreaking ALS Combination Therapy PrimeC Advances Towards commercialization in Canada; Potential for revenue in Canada alone of $100-150 million dollars. PrimeC Has Previously Demonstrated Unprecedentedly Strong Clinical Efficacy; Wall Street Maintains Buy Rating with AGP giving the company a $7.50 Price Target Representing a Significant Premium Over Current Prices; Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to dis

Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safety and tolerability profile comparable to placeboMeaningful slowing of disease progression: 29% difference (P=0.12) in favor of ALSFRS-R outcome for patients treated with PrimeC vs placeboSlow Vital Capacity: observed a positive trend in favor of patients treated with PrimeC compared to placeboNeurofilament biomarker results from Biogen collaboration expected in January 2024Primary biomarker endpoints and exploratory biomarkers from this trial, expected in H1 2024Company to host webcast conferen

 Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, today announced it will report new data from the randomized, placebo-controlled, double-blind segment of its ongoing Phase 2b amyotrophic lateral sclerosis (ALS) trial (PARADIGM) of its lead drug candidate PrimeC. The data will include primary safety and tolerability endpoints as well as secondary clinical efficacy outcome measures: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) and Slow Vital Capacity (S

CAMBRIDGE, Mass., Dec. 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update. "During and immediately following the end of the third quarter, NeuroSense achieved multiple milestones, including FDA acceptance of our IND and approval from the Italian Medicines Agency allowing us to commence patient enrollment in the U.S. and Europe for our Phase 2b ALS study, which we expect to begin in the coming weeks. With over $8.4 million in cash and short-term deposits on our balance sheet at the e

SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

SC 13G/A - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

SC 13G/A - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

SC 13G/A - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

SC 13G/A - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

SC 13G/A - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)